International Journal of Drug Policy
Volume 21, Issue 1 , Pages 86-90 , January 2010

Differences in harm from legal BZP/TFMPP party pills between North Island and South Island users in New Zealand: A case of effective industry self-regulation?

Received 18 November 2008 ,Revised 24 February 2009 ,Accepted 24 February 2009.

References 

  1. Baumann M, Clark R, Budzynski A, Partilla J, Blough B, Rothman K. Effects of “legal X” piperazine analogs on dopamine and serotonin release in rat brain. Annals of the New York Academy of Sciences. 2004;1025:189–197
  2. Baumann M, Clark R, Budzynski A, Partilla J, Blough B, Rothman R. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’). Neuropsychopharmacology. 2005;30:550–560
  3. Bye C, Munro-Faure A, Peck A, Young P. A comparison of the effects of l-benzylpiperazine on human performance tests. European Journal of Clinical Pharmacology. 1973;6:163–169
  4. Campbell H, Cline W, Evans M, et al. Comparison of the effects of dexamethamphetamine and l-benzylpiperazine in former addicts. European Journal of Clinical Pharmacology. 1973;6:170–176
  5. de Boer D, Bosman I, Hidvegi E, Manzoni C, Benko A, dos Reys J, et al. Piperazine-like compounds: A new group of designer drugs of abuse on the European market. Neuropsychopharmacology. 2005;30(3):550–560
  6. Drug Enforcement Administration (DEA) Department of Justice . Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final ruling. Federal Register. 2004;69(53):12794–12797
  7. European Monitoring Centre for Drugs and Drug Addiction. (2007). Risk assessment report of a new psychoactive substance: 1-Benzylpiperazine (BZP) (In accordance with Article 6 of Council Decision 2005/387/JHA on information exchange, risk assessment and control of new psychoactive substances). Lisbon.
  8. European Monitoring Centre for Drugs and Drug Addiction. (2008). Council decision: ‘Appropriate controls’ for BZP—new drug BZP to be placed under control across the EU (News Release No 2/2008). Lisbon.
  9. Expert Advisory Committee on Drugs. (2004). The expert advisory committee on drugs (EACD) advice to the minister on: Benzylpiperazibe (BZP). Wellington: EACD.
  10. Gee P, Richardson S, Woltersdorf W, Moore G. Toxic effects of BZP-based herbal party pills in humans: A prospective study in Christchurch, New Zealand. New Zealand Medical Journal. 2005;118(1227):1784
  11. New Zealand Herald. (2005). Restraints on party pills delayed (April 2).
  12. Sheridan J, Butler R, Wilkins C, Russell B. Legal piperazine-containing party pills—a new trend in substance misuse. Drug and Alcohol Review. 2007;26:335–343
  13. Social Tonics Association of New Zealand. (2007). Code of practice for restricted substances. November 18, 2008, from http://www.stanz.org.nz/codeofpractice.htm.
  14. Theron, L., Jansen, K., & Miles, J. (2007). ‘Benzylpiperizine-based party pills’ impact on the Auckland City Hospital Emergency Department Overdose Database (2002–2004) compared with ecstasy (MDMA or methylene dioxymethamphetamine), gamma hydroxybutyrate (GHB), amphetamines, cocaine, and alcohol. New Zealand Medical Journal, 120(1249), http://www.nzma.org.nz/journal/120-1249/2416/.
  15. Vince G. Legally high. New Scientist. 2006;191(2571):40–45
  16. Wilkins C, Girling M, Sweetsur P, Huckle T, Huakau J. Legal party pill use in New Zealand: Prevalence of use, availability, health harms and ‘gateway effects’ of benzylpiperazine (BZP) and triflourophenylmethylpiperazine (TFMPP). Auckland: Centre for Social and Health Outcomes Research and Evaluation (SHORE) & Te Ropu Whariki, Massey University; 2006;
  17. Wilkins C, Girling M, Sweetsur P. The prevalence of use, dependency and harms of legal ‘party pills’ containing benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP) in New Zealand. Journal of Substance Use. 2007;12:213
  18. Wilkins C, Sweetsur P, Girling M. Patterns of benzylpiperazine/trifluoromethylphenylpiperazine (BZP/TFMPP) party pill use and adverse effects in a population sample in New Zealand. Drug and Alcohol Review. 2008;27(6):633–639

PII: S0955-3959(09)00048-6

doi: 10.1016/j.drugpo.2009.02.005

International Journal of Drug Policy
Volume 21, Issue 1 , Pages 86-90 , January 2010

Article Tools